Based on prior data suggesting that scheduling alterations of platinum would increase activity , the aim of the present study was to assess the potential therapeutic benefit of phenoxodiol ( PXD ) , a novel biomodulator shown to have chemoresistance reversing potential , when combined with weekly AUC2-carboplatin in PROC patients .